Trial Profile
Prospective trial examining safety and biological effects of combining Ipilimumab and radiotherapy in patients with metastatic melanoma.
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Acronyms RT and Ipi in Mestatstatic Melanoma
- 04 Jun 2013 New trial record